Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director comp.
Notes underwriting agrmnt
Priveterra Acquisition Corp. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
08/22/2023 SC 13D/A Strathspey Crown Holdings, LLC reports a 5.5% stake in AEON Biopharma, Inc.
08/22/2023 DEL AM Form DEL AM - Delaying amendment:
08/18/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
07/31/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
07/31/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/28/2023 SC 13D Daewoong Co., Ltd reports a 24% stake in AEON Biopharma, Inc.
07/27/2023 8-K Director compensation was amended/approved, Entered into an underwriting agreement for the issuance and sale of notes
Docs: "THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PRIVETERRA ACQUISITION CORP. Priveterra Acquisition Corp. , a corporation organized and existing under the General Corporation Law of the State of Delaware , does hereby certify as follows: 1.            The name of the Corporation is Priveterra Acquisition Corp. The Corporation was incorporated under the name Priveterra Acquisition Corp. by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on November 17, 2020 and is being amended and restated to reflect that the Corporation has changed its name. 2.             An amended and resta...",
"AEON Biopharma, Inc. as of July 21, 2023",
"AEON BIOPHARMA, INC. AMENDED AND RESTATED 2019 INCENTIVE AWARD PLAN Effective July 21, 2023 AEON BIOPHARMA, INC. AMENDED AND RESTATED 2019 INCENTIVE AWARD PLAN 1.             Purposes of the Plan . The purposes of this AEON Biopharma, Inc. Amended and Restated 2019 Incentive Award Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’ s business. Options granted under the Plan may be Incentive Stock Options or Non-Qualified Stock Options, as determined by the Administrator at the time of grant. Stock Appreciation Rights, Stock Purchase Rights, Restri...",
"2 subject thereto upon the date of Optionee’s termination. II. AGREEMENT 1. Grant of Option. The Company hereby grants to Optionee an Option to purchase the number of Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant . Notwithstanding anything to the contrary anywhere else in this Stock Option Agreement, the Option is subject to the terms, definitions and provisions of the Plan adopted by the Company, which is incorporated herein by reference. If designated in the Notice of Grant as an Incentive Stock Option, the Option is intended to qualify as an incentive stock option as defined in Section 422 of the Code; provided, however, that to the extent that the aggregate Fair Market Value of stock with respect to which incentive stock optio...",
"US-DOCS\140721846.3 EXHIBIT A RESTRICTED STOCK UNIT AGREEMENT Capitalized terms not specifically defined in this Restricted Stock Unit Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. ARTICLE I. GENERAL 1.1 Award of RSUs. The Company has granted the RSUs to Participant effective as of the Grant Date set forth in the Grant Notice . Each RSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time the RSUs have vested. 1.2 Incorporation of Terms of Plan. The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan...",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"2 US-DOCS\137441470.5 Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. Further, Shares delivered to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation with respect to an Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards or Prior Plan Awards shall not count against the Overall Share Limit. Notwithstanding anything ...",
"2 US-DOCS\138377375.2 c. Payment of Retainers. The annual cash retainers described in Sections 1 and 1 shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than 30 days following the end of each calendar quarter. In the event an Eligible Director does not serve as a director, or in the applicable positions described in Section 1, for an entire calendar quarter, the retainer paid to such Eligible Director shall be prorated for the portion of such calendar quarter actually served as a director, or in such position, as applicable. 2. Equity Compensation. a. General. Eligible Directors shall be granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provi...",
"EXHIBI 10.11",
"EMPLOYMENT AGREEMENT"
07/24/2023 8-K Quarterly results
07/21/2023 CERT Form CERT - Certification by an exchange approving securities for listing:
07/21/2023 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
07/21/2023 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
07/21/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/20/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/18/2023 S-4MEF Form S-4MEF - Registration adding securities to prior Form S-4 registration [Rule 462(b)]:
07/17/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/17/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. FORT LAUDERDALE, FL- July 17, 2023- Priveterra Acquisition Corp. and following its name change to AEON Biopharma, Inc., “New AEON”) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock and New AEON warrants to be listed on NYSE American LLC upon the Business Combination with AEON Biopharma, Inc., following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. Trading is expected to begin on NYSE on July 24, 2023, under the new ticker symbol “AEON” for the New AEON Common Stock following the consummation of the Business Combination, which is expected to occu..."
07/11/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/11/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Priveterra Acquisition Corp. Announces Intention to Transfer to NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. FORT LAUDERDALE, FL- July 11, 2023- Priveterra Acquisition Corp. and following its name change to AEON Biopharma, Inc., “New AEON”) today announced that, upon the Business Combination with AEON Biopharma, Inc, following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc., New AEON Common Stock will be listed on NYSE American LLC . The decision to list on NYSE was made in connection with the Business Combination and enables the combined company to be listed alongside other innovative companies that are also listed on NYSE. Trading is expected to begin on NYSE on or about July 24, 2023, under..."
07/05/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/30/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/30/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination"
06/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
06/15/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/15/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
06/12/2023 SC 13G/A GLAZER CAPITAL, LLC reports a 3% stake in Priveterra Acquisition Corp.
06/08/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
05/23/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/23/2023 8-K Investor presentation
Docs: "Corporate Presentation May 2023 2 Disclaimer About This Presentation This"
05/15/2023 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy